By Michael Gwarisa THE World Health Organisation (WHO) is in the process of engaging Pharmaceutical and drug manufacturing companies to negotiate on the pricing of second line Anti Retro-viral drugs to assist Zimbabwe and other struggling third world countries to ensure they access the lifesaving drugs at affordable prices. The development come in the midst of reports that Zimbabwe is experiencing massive second line Abacavir ARV drug stock-outs, putting more than 30 000 lives at risk of developing HIV drug resistance owing to discontinued uptake of ARVs. Briefing Journalists in…
Read MoreWHO Moves To Curb 2nd Line ARV Stock-outs
